Use of irak4 modulators for gene therapy
AssigneeGenzyme Corporation
InventorsSourav Roy CHOUDHURY, Mona MOTWANI, Christian MUELLER, John REED
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK modulator (e.g., an IRAK-4 degrader) with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK modulator in combination with a gene therapy agent.
Claims30
A method for delivering nucleic acid to a cell of an individual in need thereof, the method comprising
- a) administering an IRAK modulator to the individual, and
- b) administering a gene therapy agent to the individual.
A method for treating an individual in need thereof with a gene therapy agent, the method comprising
- a) administering an IRAK modulator to the individual, and
- b) administering the gene therapy agent to the individual.
A method for improving gene therapy in an individual, the method comprising
- a) administering an IRAK modulator to the individual, and
- b) administering a gene therapy agent to the individual.
A method for suppressing an immune response to a gene therapy agent in an individual in need thereof, the method comprising
- a) administering an IRAK modulator to the individual, and
- b) administering a gene therapy agent to the individual.
(canceled)
(canceled)
19-32. (canceled)
-37. (canceled)
A method for treating an individual in need thereof with a gene therapy agent, the method comprising
- a) incubating innate immune cells from the individual with the gene therapy agent,
- b) analyzing the innate immune cells for the expression of one or more cytokines wherein expression of a cytokine signature following incubation with the gene therapy agent identifies an individual with innate immunity to the gene therapy agent,
- c) administering an IRAK modulator to the individual identified in step b), and
- d) administering the gene therapy agent to the individual identified in step b).
A method for selecting an individual for treatment with a gene therapy agent and an IRAK modulator, the method comprising
- a) incubating innate immune cells from the individual with the gene therapy agent,
- b) analyzing the innate immune cells for the expression of one or more cytokines wherein expression of a cytokine signature following incubation with the gene therapy agent identifies an individual for treatment with a gene therapy agent and an IRAK modulator.
- c) selecting the individual identified in step b) for treatment with a gene therapy agent and an IRAK modulator.
40-47. (canceled)
49-59. (canceled)
61-109. (canceled)
Dependencies are inferred from the claim text.